staceywhite, Author at European Medical Journal - Page 36 of 195

The ITP Treatment Landscape

In this video, discover updates in the treatment of immune thrombocytopaenia, with a focus on patient perspectives and unmet clinical needs.

Early Intervention in Osteoarthritis: An Interactive Case Study

With osteoarthritis prevalence rising globally, this interactive case study was designed to highlight the patient journey of a someone with early-stage knee osteoarthritis

Lebrikizumab▼: Short and Long-Term Disease Control in Moderate-to-Severe AD Through Selective IL-13 Inhibition

This infographic highlights how Lebrikizumab, a selective IL-13 inhibitor, provides short- and long-term disease control in…

Early Recognition, Diagnosis, and Treatment of Friedreich Ataxia

At the 2024 European Association of Neurology (EAN) Congress, one satellite symposium discussed the recognition, diagnosis, and treatment…

Clinical Practice Insights for Hyperpigmentation Treatment

Hyperpigmentation disorders, a group of common skin conditions characterised by darkened patches due to excess melanin production, affect…

The ITP Treatment Landscape

The limitations of currently available therapies for immune thrombocytopenia (ITP) mean that long-term responses are difficult to maintain…

Answering the Patient’s Call: A Move Towards Personalized Primary Biliary Cholangitis Care

The key to personalized care for patients with primary biliary cholangitis (PBC) starts with good and effective dialogue between the…

Driving change within the PFIC landscape

A lot has changed within the Progressive Familial Intrahepatic Cholestasis (PFIC) landscape in the last few years. The introduction of…

early diagnosis of Alzheimer's disease: a blue cartoon brain on a pink background

Early Diagnosis of Alzheimer's Disease: Why You Should Care

The landscape is shifting from symptom management to identifying early stage Alzheimer’s Disease and addressing the underlying mechanisms of disease.

Transforming Management of Indolent Systemic Mastocytosis With Precision Medicine

Systemic mastocytosis (SM) is driven by KIT D816V mutation in approximately 95% of cases. With the emergence of targeted treatments for…